DelveInsight’s, “HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in HER2-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ HER2-mutant Non-Small Cell Lung Cancer Pipeline Outlook
Key Takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
Stay informed about the cutting-edge advancements in HER2-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ HER2-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment
HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile
DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.
Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.
Learn more about HER2-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking HER2-mutant Non-Small Cell Lung Cancer Research and development projects @ HER2-mutant Non-Small Cell Lung Cancer Unmet Needs
HER2-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
HER2-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
Discover the latest advancements in HER2-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ HER2-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of HER2-mutant Non-Small Cell Lung Cancer Pipeline on our website @ HER2-mutant Non-Small Cell Lung Cancer Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services